However, in the recent plasma-MATCH Phase II study in a heavily pretreated patient population that assessed the feasibility and utility of ctDNA in directing targeted therapy in breast cancer, fulvestrant demonstrated similar activity in patients with and without ESR1 gene mutations in plasma, suggesting more complex clonal dynamics at play [44]. Here, ESR1 is linked to breast cancer.